. M  a  c  C  a  l  l  u  m  C  a  n  c  e  r  C  e  n  t  e  r  ,  3  0  5  G  r  a  t  t  a  n  S  t  r  e  e  t  ,  M  e  l  b  o  u  r  n  e  ,  V  i  c  t  o  r  i  a  ,  3  0  0  0  ,  A  u  s  t  r  a  l  i  a  .  7  1  .  S  i  r  P  e  t  e  r  M  a  c  C  a  l  l  u  m  D  e  p  a  r  t  m  e  n  t  o  f  O  n  c  o  l  o  g  y  ,  T  h  e  U  n  i  v  e  r  s  i  t  y  o  f  M  e  l  b  o  u  r  n  e  ,  3  0  5  G  r  a  t  t  a  n  S  t  r  e  e  t  ,  M  e  l  b  o  u  r  n  e  ,  V  i  c  t  o  r  i  a  ,  3  0  0  0  ,  A  u  s  t  r  a  l  i  a  .  7  2  .  S  o  r  b  o  n  n  e  U  n  i  v  e  r  s  i  t  é  ,  G  R  C  N  °  5  O  N  C  O  T  Y  P  E  -U  R  O  ,  T  e  n  o  n  H  o  s  p  i  t  a  l  ,  P  a  r  i  s  ,  F  r  a  n  c  e  .  7  3  .  C  e  R  e  P  P  ,  T  e  n  o  n  H  o  s  p  i  t  a  l  ,  P  a  r  i  s  ,  F  r  a  n  c  e  .  7  4 . h  e  m  i  s  t  r  y  ,  D  e  p  a  r  t  m  e  n  t  o  f  M  e  d  i  c  a  l  B  i  o  s  c  i  e  n  c  e  s  ,  U  m  e  å  U  n  i  v  e  r  s  i  t  y  ,  B  y  6  M  v  a  n  2  ,  S  j  u  k  h  u  s  o  m  r  a  d  e  t  ,  U  m  e  a  u  n  i  v  e  r  s  i  t  e  t  ,  U  m  e  a  ,  9  0  1  8  5  ,  S  w  e  d  e  n  .  1  3  8  .  C  l  i  n  i  c  a  l  G  e  n  e  t  i  c  s  B  r  a  n  c  h  ,  D  C  E  G  ,  N  a  t  i  o  n  a  l  C  a  n  c  e  r  I  n  s  t  i  t  u  t  e  ,  9  6  0  9  M  e  d  i  c  a  l  C  e  n  t  e  r  D  r  ,  B  e  t  h  e  s  d  a  ,  M  D  ,  2  0  8  5  0  -9  7  7  2  ,  U  S  A  .  1  3  9 . . s  i  v  e  C  a  n  c  e  r  C  e  n  t  e  r  ,  G  e  o  r  g  e  t  o  w  n  U  n  i  v  e  r  s  i  t  y  ,  3  8  0  0  R  e  s  e  r  v  o  i  r  R  o  a  d  ,  W  a  s  h  i  n  g  t  o  n  ,  D  C  ,  2  0  0  0  7  ,  U  S  A  .  1  6  1  .  I  n  d  e  p  e  n  d  e  n  t  L  a  b  o  r  a  t  o  r  y  o  f  M  o  l  e  c  u  l  a  r  B  i  o  l  o  g  y  a  n  d  G  e  n  e  t  i  c  D  i  a  g  n  o  s  t  i  c  s  ,  P  o  m  e  r  a  n  i  a  n  M  e  d  i  c  a  l  U  n  i  v  e  r  s  i  t  y  ,  R  y  b  a  c  k  a  1  ,  7  0  -2  0  4  S  z  c  z  e  c  i  n  ,  P  o  l  a  n  d  .  1  6  2 . o  p  u  l  a  t  i  o  n  S  c  i  e  n  c  e  s  ,  B  e  c  k  m  a  n  R  e  s  e  a  r  c  h  I  n  s  t  i  t  u  t  e  o  f  C  i  t  y  o  f  H  o  p  e  ,  1  5  0  0  E  D  u  a  r  t  e  ,  C  A  ,  9  1  0  1  0  ,  U  S  A  .  2  2  9  .  D  e  p  a  r  t  m  e  n  t  o  f  O  b  s  t  e  t  r  i  c  s  a  n  d  G  y  n  e  c  o  l  o  g  y  ,  H  e  l  s  i  n  k  i  U  n  i  v  e  r  s  i  t  y  H  o  s  p  i  t  a  l  ,  U  n  i  v  e  r  s  i  t  y  o  f  H  e  l  s  i  n  k  i  ,  H  a  a  r  t  m  a  n  i  n  k  a  t  u  8  ,  H  e  l  s  i  n  k  i  ,  0  0  2  9  0  ,  F  i  n  l  a  n  d  .  2  3  0 . o  l  e  c  u  l  a  r  B  a  s  e  s  o  f  G  e  n  e  t  i  c  R  i  s  k  a  n  d  G  e  n  e  t  i  c  T  e  s  t  i  n  g  ,  D  e  p  a  r  t  m  e  n  t  o  f  R  e  s  e  a  r  c  h  ,  F  o  n  d  a  z  i  o  n  e  I  R  C  C  S  (  I  s  t  i  t  u  t  o  D  i  R  i  c  o  v  e  r  o  e  C  u  r  a  a  C  a  r  a  t  t  e  r  e  S  c  i  e  n  t  i  f  i  c  o  )  I  s  t  i  t  u  t  o  N  a  z  i  o  n  a  l  e  d  e  i  T  u  m  o  r  i  (  I  N  T  )  ,  V  i  a  G  i  a  c  o  m  o  V  e  n  e  z  i  a  n  1  ,  M  i  l  a  n  ,  2  0  1  3  3  ,  I  t  a  l  y  .  2  5  3  .  D  e  c  o  d  e  g  e  n  e  t  i  c  s  ,  S  t  u  r  l  u  g  a  t  a  8  ,  I  S  -1  0  1  R  e  y  k  j  a  v  i  k  ,  I  c  e  l  a  n  d  ,  R  e  y  k  j  a  v  i  k  ,  I  c  e  l  a  n  d  .  2  5  4 . Our comprehensive analysis identifies statistically significant genetic correlations between lung and head/neck cancer, breast and ovarian cancer, breast and lung cancer and breast and colorectal cancer.
We also find multiple cancers to be genetically correlated with non-cancer traits including smoking, psychiatric diseases and metabolic traits. Functional enrichment analysis reveals a significant contribution of conserved and regulatory regions to cancer heritability. Our results suggest that solid tumors arising across tissues share in part a common germline genetic basis.
RESULTS

Heritability estimates across cancers
We first estimated cancer-specific heritability causally explained by common SNPs (݄ ଶ ) using LDSC (note that this quantity is slightly different from the ݄ ଶ Table 2 ), we observed an ~50% decrease in SNP-heritability for prostate and breast cancer, and ~20% decrease for lung, ovarian and colorectal cancer, despite the fact that we were only excluding 1% (colorectal cancer) to 5% (breast cancer) of the genome. In contrast, the SNPheritability for head/neck cancer was not affected by removing genome-wide significant loci (Fig. 1A) .
For most of the cancers, the GWAS significant loci for that particular cancer explained most of the heritability. For some cancers, however, significant GWAS loci of other cancers also explained a nontrivial part of its heritability. For example, the significant breast cancer GWAS loci explained 10%, 15%
and 22% heritability of colorectal, ovarian and prostate cancer, respectively; the significant colorectal cancer GWAS loci explained 11% heritability of prostate cancer; the significant lung cancer GWAS loci explained 10% heritability of head/neck cancer; and the significant prostate cancer GWAS loci explained 11% and 15% heritability of breast and ovarian cancer, respectively ( Supplementary Table 3 ).
Comparing the liability-scale SNP-heritability to corresponding estimates from twin studies suggests that common SNPs can almost entirely explain the classical heritability of head/neck cancer, whereas for other cancers, only 30-40% of heritability can be explained (Fig. 1B) .
Genetic correlations between cancers
We then estimated the genetic correlation between cancers using cross-trait LDSC (see Methods). After adjusting for the number of tests (p<0.05/15=0.003), we found multiple significant genetic correlations Fig. 1C, Supplementary Table 1 1C ). Some cancer pairs showed minimal correlations with estimates close to 0 (ovarian and prostate: ‫ݎ‬ =0.02, se=0.07; lung and prostate: ‫ݎ‬ = −0.03, se=0.04; breast and head/neck: ‫ݎ‬ =0.03, se=0.06). We further calculated the cross-cancer genetic correlation based on data after excluding the GWAS significant regions of each cancer. The estimates were mostly consistent with the results calculated based on all SNPs (data not shown).
We conducted subtype-specific analysis for breast, lung, ovarian and prostate cancer ( Supplementary   Table 1 ). Estrogen receptor (ER)+ and ER− breast cancer showed a genetic correlation of 0.60 (se=0.03),
indicating that the genetic contributions to these two subtypes are in part distinct. The genetic correlation between the two common lung cancer subtypes adenocarcinoma and squamous cell carcinoma was similarly 0.58 (se=0.10). Further, we observed a significantly larger genetic correlation of lung cancer with ER− ‫ݎ(‬ =0.29, se=0.06) than with ER+ breast cancer ‫ݎ(‬ =0.13, se=0.04) (p difference =0.002). This also held true for lung squamous cell carcinoma, which showed statistically stronger genetic correlation with ER− ‫ݎ(‬ =0.33, se=0.08) than with ER+ breast cancer ‫ݎ(‬ =0.11, se=0.05) (p difference =0.0019). We observed no other statistically significant differential genetic correlations across subtypes (all p difference >0.1).
We then estimated local genetic correlations between cancers using ρ-HESS, dividing the genome into 1,703 regions (see Methods) ( Fig. 2 and Supplementary Fig 1) . We found that although the genomewide genetic correlation between breast and prostate cancer was modest ( ‫ݎ‬ =0.07), chr10:123M (10q26.13, p=1.0×10 -7 ) and chr9:20-22M (9p21, p=1.0×10 -6 ), two previously known pleiotropic regions 18 , showed significant genetic correlations ‫ݎ(‬ = −0.00098 and ‫ݎ‬ = 0.00046). Similarly, although the genome-wide genetic correlation between lung and prostate cancer was negligible ‫ݎ(‬ = −0.03), two previously identified pleiotropic regions (chr6:30-31M or 6p21.33, p=5.7×10 -7 and chr20:62M or 20q13.33, p=2.8×10 -6 ) exhibited significant local genetic correlations ‫ݎ(‬ = −0.00060 and ‫ݎ‬ = 0.00067).
Overall, local genetic correlation analysis reinforced shared effects for 44% (31/71) of previously reported pleiotropic cancer regions ( Supplementary Table 4 ). It also identified novel pleiotropic signals.
For example, the breast and prostate cancer pleiotropic region at 2q33.1 showed significant local genetic correlation between breast and ovarian cancer (p=2.3×10 -6 ). Additionally, 6p21.32, a region indicated for head/neck and prostate cancer, showed highly significant local genetic correlation for head/neck and lung cancer (p=8.6×10 -8 ).
Genetic correlations between cancer and other traits
Significant genetic correlations (p<0.05/228=0.0002) between the six cancers and 38 non-cancer traits reflected several known associations ( Fig. 3 and Supplementary Table 5 ). We observed a strong genetic correlation between smoking and lung cancer ‫ݎ(‬ We did not find evidence of genetic correlations between cancer and several previously suggested risk factors 21-23 including cardiovascular traits (coronary artery disease, hypertension and blood pressure) or sleep characteristics (chronotype, duration and insomnia). Further, we did not observe genetic correlations between cancer and circulating lipids (HDL, LDL, triglycerides) or type 2 diabetes-related traits except a significant negative correlation between HDL and lung cancer ‫ݎ(‬ = −0.14, se=0.04). We observed no significant genetic correlation between breast cancer and age at menarche ‫ݎ(‬ = −0.03, se=0.03) or age at natural menopause ‫ݎ(‬ = −0.01, se=0.03). We also did not observe notable genetic correlations between cancer and autoimmune inflammatory diseases or height.
Subtype analysis revealed that smoking and educational attainment showed genetic correlations with all lung cancer subtypes ( Supplementary Table 5 ). Educational attainment, forced vital capacity and depressive symptoms showed genetic correlations with ER− but not ER+ breast cancer, whilst the observed genetic correlation between schizophrenia and breast cancer was limited to ER+ disease, and the genetic correlation between depressive symptoms and lung cancer was observed only for lung squamous cell carcinoma.
We further assessed the support for mediated or pleiotropic causal models for non-cancer traits and cancer using the correlation between trait-specific effect sizes of genome-wide significant SNPs for pairs of phenotypes. We detected four putative directional genetic correlations (defined as p<0.05 from a likelihood ratio (LR) comparing the best non-causal model to the best causal model) ( Fig. 4) 
Functional enrichment analysis of cancer heritability
Finally, we partitioned SNP-heritability of each cancer by using 24 genomic functional annotations (the baseline-LD model described in Gazal et al. 24 ) and 220 cell-type-specific histone mark annotations (the cell-type-specific model described in Finucane et al. 14 ) . Meta-analysis across the six cancers revealed statistical significant enrichments for multiple functional categories. We observed the highest enrichment for conserved regions (Table 1 , Supplementary Table 6 ) which overlapped with only 2.6%
of SNPs but explained 25% of cancer SNP-heritability (9.8-fold enrichment, p=2.3×10 -5 ). Transcription factor binding sites showed the second highest enrichment (4.0-fold, 13% of SNPs explaining 40% of SNP-heritability, p=1.4×10 -7 ). Further, super-enhancers (groups of putative enhancers in close genomic proximity with unusually high levels of mediator binding) showed a significant 2.6-fold enrichment (p=2.0×10 -20 ). Additional enhancers, including regular enhancers (3.2-fold), weak enhancers (3.1-fold) and FANTOM5 enhancers (3.1-fold), presented similar enrichments but were not statistically significant.
In addition, multiple histone modifications of epigenetic markers H3K9ac, H3K4me3 and H3K27ac, were all significantly enriched for cancer heritability. Repressed regions exhibited depletion (0.34-fold, p=1.2×10 -6 ). Enrichment analysis of functional categories for each cancer subtype are shown in Supplementary Table 7 .
Overall, cell-type-specific analysis of histone marks identified significant enrichments specific to individual cancers ( Supplementary Fig. 2) . For breast cancer, 3 out of 8 statistically significant tissues were adipose nuclei (H3K4me1, H3K9ac) and breast myoepithelial (H3K4me1) cells. For colorectal cancer, 15 out of the 18 statistical significant enrichments were observed in either colon or rectal tissues (colon/rectal mucosa, duodenum mucosa, small/large intestine and colon smooth muscle). We observed no significant enrichments for head/neck, lung and ovarian cancer, but we noted that for both lung (9 out of 10) and ovarian cancer (6 out of 10), the most enriched cell types were immune cells; while in head/neck cancer, 6 out of 10 most highly enriched cell types belonged to CNS ( Supplementary Fig. 3 , Supplementary Table 8 ). Cell-type-specific analysis for cancer subtypes are shown in Supplementary   Table 9 . Comparing cell-type-specific enrichment for cancers to the additional 38 non-cancer traits revealed notably differential clustering patterns ( Supplementary Fig. 4 ). Breast, colorectal and prostate cancer showed enrichment mostly for adipose and epithelial tissues, in contrast to autoimmune diseases (enriched for immune/hematopoietic cells) or psychiatric disorders (enriched for brain tissues).
DISCUSSION
We performed a comprehensive analysis quantifying the heritability and genetic correlation of six cancers, leveraging summary statistics from the largest cancer GWAS conducted to date. Our study demonstrates shared genetic components across multiple cancer types. These results contrast with a prior study conducted by Sampson et al. which reported an overall negligible genetic correlation among common solid tumors. 9 Our results are, however, in line with a recent study 16 which analyzed a subset of the data included here, and identified a significant genetic correlation between lung and colorectal cancer.
Our data support, and for the first time quantify, the strong genetic correlation ‫ݎ(‬ =0.57) between lung and head/neck cancer, two cancers linked to tobacco use. 20, 25 We also for the first time observed a significant genetic correlation between breast and ovarian cancer ሺ ‫ݎ‬ Heritability analysis confirms that common cancers have a polygenic component that involves a large number of variants. Although susceptibility variants identified at genome-wide significance explain an appreciable fraction of the heritability for some cancers, we estimate that the majority of the polygenic effect is attributable to other, yet undiscovered variants, presumably with effects that are too weak to have been identified with current sample sizes. We found the genetic component that could be attributed to genome-wide significant loci varied greatly from ~0% for head/neck cancer to ~50% for breast and prostate cancer. These results reflect in part the strong correlation between number of GWAS-identified loci and sample size, as we had more than twice as many breast and prostate cancer samples compared to the other cancers. One corollary is that larger GWAS are likely to identify new susceptibility loci that could help our understanding of disease development, improve prediction power of genetic risk scores and hence contribute to screening and personalized risk prediction. 29
Among the genetic correlations between cancer and non-cancer traits, we observed positive correlations for psychiatric disorders (depressive symptoms, schizophrenia) with lung and breast cancer, where findings from epidemiological studies have been suggestive but inconclusive. It has been proposed that the linkage between psychiatric traits and cancers are more likely to be mediated through cancer- which has been shown to be true for multiple traits. 14, 40 Even though the biochemical function of many conserved regions remains uncharacterized, transcribed ultra-conserved regions have been found to be frequently located at fragile sites. Compared to normal cells, cancer cells have a unique spectrum of transcribed ultra-conservative regions, suggesting that variation in expression of these regions are involved in the malignant process. 41, 42 These results bridge the link between germline and somatic genetics in cancer development, which was also observed in a recent breast cancer GWAS that has demonstrated a strong overlap between target genes for GWAS hits and somatic driver genes in breast tumors. 43 We also found a four-fold enrichment for transcription factor binding sites and a three-fold enrichment for super enhancers, consistent with prior observations that breast cancer GWAS loci fall in enhancer regions involved in distal regulation of target genes. 43 Cell type-specific analysis of histone marks demonstrated the importance of tissue specificity, primarily for colorectal and breast cancer.
Further, our results suggest that immune cells are important for ovarian and lung cancer whilst CNS is important to head/neck cancer. Unfortunately, we did not have data on prostate-specific tissues but we note that tissue-specific enrichment of prostate cancer heritability for epigenetic markers has been observed previously. 10 We note that generation of rich functional annotation is ongoing and we expect to include additional tissue-specific functional elements in our future work.
Our study has several strengths. We were able to robustly quantify pair-wise genetic correlations between multiple cancers using the largest available cancer GWAS, comprising almost 600,000 samples across six major cancers and subtypes. We were also able to systematically assess the genetic correlations between cancer and 38 non-cancer traits. Notwithstanding the large sample sizes, several limitations need to be acknowledged. We did not have the sample sizes required to assess relevant cancer subgroups including oropharyngeal cancer, clear cell, mucinous and endometrioid ovarian cancer, or lung cancer among never smokers (each with ~2,000 cases). In addition, we did not have access to GWAS summary statistics for pre-vs. post-menopausal breast cancer. We were not able to consider all cancer risk factors when selecting non-cancer traits, since some of the well-established risk factors such as infection were either not available, showed no evidence of heritability or were not based on adequate sample sizes for robust analyses. SNP-heritability varies with minor allele frequency, linkage disequilibrium and genotype certainty; we note that approaches to estimate heritability leveraging GWAS data are constantly evolving. We also note that estimate variability needs to be taken into account when comparing the SNP-heritability with the classical twin-heritability, in particular for cancers with small sample sizes such as head/neck cancer (SNP-heritability varied between 5-14% and twin-heritability varied between 0-60%, although both point estimates were 9%). Further, our data were based on GWAS meta-analysis from multiple individual GWAS across European ancestry populations from Europe, Australia and the US. Intra-European ancestry differences are likely to be a source of bias.
However, since we limited our analysis to SNPs with MAF>1% and HapMap3 SNPs (which have proven to be well-imputed across European ancestry populations), we believe that any population structure across cancers will have minimal effect on our results. Finally, as more non-European and multi-ethnic GWAS data become available, it is important to examine trans-ethnic genetic correlation in cancer.
In conclusion, results from our comprehensive analysis of heritability and genetic correlations across six cancer types indicate that solid tumors arising from different tissues share common germline genetic influences. Our results also demonstrate evidence for common genetic risk sharing between cancers and smoking, psychiatric and metabolic traits. In addition, functional components of the genome, particularly conserved and regulatory regions, are significant contributors to cancer heritability across multiple cancer types. Our results provide a basis and direction for future cross-cancer studies aiming to further explore the biological mechanisms underlying cancer development.
METHODS
Studies and quality control
We used summary statistics from six cancer GWASs based on a total of 597,534 participants of : 29,266 / 56,450; ovarian cancer: 22,406 / 40,941; prostate cancer: 79,166 / 61,106 . These data were generated through the joint efforts of multiple consortia. Details on study characteristics and subjects contributed to each cancer-specific GWAS summary dataset have been described elsewhere. [43] [44] [45] [46] [47] [48] [49] SNPs were imputed to the 1000 Genomes Project reference panel (1KGP) using a standardized protocol for all cancer types. 18 We included autosomal SNPs with a minor allele frequency (MAF) larger than 1% and present in HapMap3 (N SNPs = ~1 million) because those SNPs are usually well imputed in most studies (note that excluding sex chromosomes could reduce the overall heritability estimates). A brief overview of the quality control in each cancer dataset are presented in Supplementary Table 10 .
For some of the cancers, we further obtained summary statistics data on subtypes (ER+ and ER− breast cancer; lung adenocarcinoma and squamous cell carcinoma; serous invasive ovarian cancer and advanced stage prostate cancer, defined as metastatic disease or Gleason score≥8 or PSA>100 or prostate cancer death). Sample sizes and more details shown in Supplementary Table 1 .
We additionally assembled European ancestry GWAS summary statistics from 38 traits, which spanned a wide range of phenotypes including anthropometric (e.g., height and body mass index (BMI)), psychiatric disorder (e.g., depressive symptoms and schizophrenia) and autoimmune disease (e.g., rheumatoid arthritis and celiac disease) ( Supplementary Table 11 ). We calculated trait-specific SNPheritability and restricted our analysis to traits with a heritable component ( Supplementary Table 12 ) as previously proposed. 14 We removed the major histocompatibility complex (MHC) region from all analysis because of its unusual LD and genetic architecture.
Estimation of SNP-heritability and genetic correlation
We estimated the SNP-heritability due to genotyped and imputed SNPs ( ݄ ଶ , the proportion of phenotypic variance causally explained by common SNPs) of each cancer using LDSC. 15 Briefly, this method is based on the relationship between LD score and χ 2 -statistics:
denotes the expected χ 2 -statistics for the association between the outcome and SNP j, N j is the study sample size available for SNP j, M is the total numbers of variants and ݈ denotes the LD score identified SNPs that were associated with a given cancer at genome-wide significance (p<5×10 -8 ) and
removed all SNPs +/− 500,000 base-pairs of those loci prior to calculation (number of regions (+/− 500 kb) for each cancer that reach the 5×10 -8 threshold and measures of effect size are shown in Supplementary Table 2 ). We also converted the SNP-heritability from observed scale to liability scale by incorporating sample prevalence (P) and population prevalence (F) of each cancer:
We subsequently calculated the genome-wide genetic correlations ‫ݎ(‬ ) between different cancers, and between cancers and non-cancer traits, using an algorithm as previously described: 14
where β j and γ j are the effect sizes of SNP j on traits 1 and 2, ‫ݎ‬ is the genetic covariance, M is number of SNPs, N 1 and N 2 are the sample sizes for trait 1 and 2, N s is the number of overlapping samples, r is the phenotypic correlation in overlapping samples and l j is the LD score defined as above. For genetic correlation between 6 cancers, the significance level is 0.05/15 = 0.003; for genetic correlation between 6 cancers and 38 traits, the significance level is 0.05/(6×38) = 0.0002.
Overall genetic correlations as estimated by LDSC are based on aggregated information across all variants in the genome. It is possible that even though two traits show negligible overall genetic correlation, there are specific regions in the genome that contribute to both traits. We therefore examined local genetic correlations between cancer pairs using ρ-HESS, 50 an algorithm which partitions the whole genome into 1,703 regions based on LD-pattern of European populations and quantifies correlation between pairs of traits due to genetic variation restricted to these genomic regions. Local genetic correlation was considered statistically significant if p<0.05/1,703=2.9×10 -5 . In particular, we assessed the local genetic correlations for previously reported pleiotropic regions 18,51 known to harbor SNPs affecting multiple cancers.
Directional genetic correlation analysis
In addition to the genetic correlation analysis which reflects overall genetic overlaps, we also attempted to identify directions of potential genetic correlations using a subset of SNPs as proposed by Pickrell et al. 52 The method adopts the following assumption: if a trait X influences trait Y, then SNPs influencing X should also influence Y, and the SNP-specific effect sizes for the two traits should be correlated.
Further, since Y does not influence X, but could be influenced by mechanisms independent of X, genetic variants that influence Y do not necessarily influence X. Based on this assumption, the method proposes two "causal" models and two "non-causal" models, and calculates the relative likelihood ratio (LR) of the best non-causal model compared to the best causal model. We determined significant SNPs for each given cancer or trait in two independent ways, 1) LD pruned SNPs: we selected genome-wide significant (p<5×10 -8 ) SNPs and pruned on LD-pattern in the European populations in Phase1 of 1KGP; 2) posterior probability of association (PPA) SNPs: we used a method implemented in "fgwas" 53 , which splits the genome into independent blocks based on LD-patterns in 1KGP and estimates the prior probability that any block contains an association. The model outputs posterior probability that the region contains a variant that influences the trait. We selected the lead SNP from each of the regions with a PPA of at least 0.9. We scanned through all pairs of cancers and traits to identify directional correlations. Only pairs of traits with evidence of directional correlations (LR comparing the best noncausal model over the best causal model<0.05) and without evidence of heteroscedasticity (pleiotropic effects) 54 were reported as relatively more likely to exhibit mediated causation.
Functional partitioning of SNP-heritability
To assess the importance of specific functional annotations in SNP-heritability across cancers, we partitioned the cancer-specific heritability using stratified-LDSC. 14 2) In addition to the baseline-LD model, we also performed analyses using 220 cell-type-specific annotations for the four histone marks H3K4me1, H3K4me3, H3K9ac and H3K27ac. Each cell-typespecific annotation corresponds to a histone mark in a single cell type (for example, H3K27ac in CD19 immune cells), and there were 220 such annotations in total. We further divided these 220 cell-typespecific annotations into 10 groups (adrenal and pancreas, central nervous system (CNS), cardiovascular, connective and bone, gastrointestinal, immune and hematopoietic, kidney, liver, skeletal muscle, and other) by taking a union of the cell-type-specific annotations within each group (for example, SNPs with any of the four histone modifications in any hematopoietic and immune cells were considered as one big category). When generating the cell-type-specific models, we added annotations individually to the baseline model, creating 220 separate models.
We performed a random-effects meta-analysis of the proportion of heritability over six cancers for each functional category. We set significance thresholds for individual annotations at p<0.05/24 for baseline model and at p<0.05/220 for cell-type-specific annotation.
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